The Commission has approved under the EU Merger Regulation the proposed acquisition by Pfizer of fellow US pharmaceutical and health products company Wyeth, provided that the merged entity makes certain divestments. The Commission’s investigation found that, while the companies’ human healthcare activities were largely complementary, the transaction as originally proposed would have led to competition issues in several national markets for the supply of animal health products, potentially leading to restricted choice and higher prices for consumers. Accordingly, Pfizer offered commitments to make a number of divestments, including the sale of businesses supplying feline and equine vaccines, sedatives, antibiotics, paraciticides and rehydration salts, as well as the disposal of an Irish manufacturing facility. The Commission’s view was that these divestments were sufficient to assuage any concerns about the transaction’s impact on competition.